Concerning the relationships between genes, risk factors and immunity in Alzheimer's disease, Autism, Bipolar disorder , multiple sclerosis, Parkinson's disease, schizophrenia and chronic fatigue
Solanezumab, an experimental Eli Lilly medication for Alzheimer's disease, slowed the rate of cognitive decline and memory loss by approximately 30% among patients in early stages of the disease. MNT
No comments:
Post a Comment